The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic
- PMID: 32358216
- PMCID: PMC7371383
- DOI: 10.1212/WNL.0000000000009698
The CREST-2 experience with the evolving challenges of COVID-19: A clinical trial in a pandemic
Abstract
The coronavirus disease 2019 pandemic has disrupted the lives of whole communities and nations. The multinational multicenter National Institute of Neurological Disorders and Stroke Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial stroke prevention trial rapidly experienced the effects of the pandemic and had to temporarily suspend new enrollments and shift patient follow-up activities from in-person clinic visits to telephone contacts. There is an ethical obligation to the patients to protect their health while taking every feasible step to ensure that the goals of the trial are successfully met. Here, we describe the effects of the pandemic on the trial and steps that are being taken to mitigate the effects of the pandemic so that trial objectives can be met.
© 2020 American Academy of Neurology.
References
-
- Murray CJL. Forecasting COVID-19 impact on hospital bed-days, ICU-days, ventilator days and deaths by US state in the next 4 months. IMHE web page. Avaiable at: healthdata.org/research-article/forecasting-covid-19-impact-hospital-bed.... Accessed April 2, 2020.
-
- Trachtman H, Caplan A. Data monitoring committees and stopping trials—giving participants a voice. Contemp Clin Trials 2018;68:146. - PubMed
-
- Cassileth BR, Lusk EJ, Miller DS, Hurwitz S. Attitudes toward clinical trials among patients and the public. JAMA 1982;248:968–970. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous